Differentiation Between Oligodendroglioma Genotypes Using Dynamic Susceptibility Contrast Perfusion-weighted Imaging and Proton MR Spectroscopy

Overview

Journal AJNR Am J Neuroradiol

Specialty Neurology

Date 2013 Feb 2

PMID 23370479

Citations 41

Authors

S Chawla

J Krejza

A Vossough

Y Zhang

G S Kapoor

S Wang

D M ORourke

E R Melhem

H Poptani

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Oligodendrogliomas with 1p/19q chromosome LOH are more sensitive to chemoradiation therapy than those with intact alleles. The usefulness of dynamic susceptibility contrast-PWI-guided ¹H-MRS in differentiating these 2 genotypes was tested in this study.

Materials And Methods: Forty patients with oligodendrogliomas, 1p/19q LOH (n = 23) and intact alleles (n = 17), underwent MR imaging and 2D-¹H-MRS. ¹H-MRS VOI was overlaid on FLAIR images to encompass the hyperintense abnormality on the largest cross-section of the neoplasm and then overlaid on CBV maps to coregister CBV maps with ¹H-MRS VOI. rCBVmax values were obtained by measuring the CBV from each of the selected ¹H-MRS voxels in the neoplasm and were normalized with respect to contralateral white matter. Metabolite ratios with respect to ipsilateral Cr were computed from the voxel corresponding to the rCBVmax value. Logistic regression and receiver operating characteristic analyses were performed to ascertain the best model to discriminate the 2 genotypes of oligodendrogliomas. Qualitative evaluation of conventional MR imaging characteristics (patterns of tumor border, signal intensity, contrast enhancement, and paramagnetic susceptibility effect) was also performed to distinguish the 2 groups of oligodendrogliomas.

Results: The incorporation of rCBVmax value and metabolite ratios (NAA/Cr, Cho/Cr, Glx/Cr, myo-inositol/Cr, and lipid + lactate/Cr) into the multivariate logistic regression model provided the best discriminatory classification with sensitivity (82.6%), specificity (64.7%), and accuracy (72%) in distinguishing 2 oligodendroglioma genotypes. Oligodendrogliomas with 1p/19q LOH were also more associated with paramagnetic susceptibility effect (P < .05).

Conclusions: Our preliminary results indicate the potential of combing PWI and ¹H-MRS to distinguish oligodendroglial genotypes.

Citing Articles

Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O-methylguanine-methyltransferase promoter methylation status.

Yadav V, Mohan S, Agarwal S, de Godoy L, Rajan A, Nasrallah M Neurooncol Adv. 2024; 6(1):vdae159.

PMID: 39502470 PMC: 11535496. DOI: 10.1093/noajnl/vdae159.

Multiparametric simultaneous hybrid F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (F-FDG PET/MRI) incorporating intratumoral and peritumoral regions for grading of glioma.

Liu P, Zeng Y, Qu H, Zheng W, Zhou T, Hang L Quant Imaging Med Surg. 2024; 14(8):5665-5681.

PMID: 39144048 PMC: 11320556. DOI: 10.21037/qims-24-280.

Tumor-like Lesions in Primary Angiitis of the Central Nervous System: The Role of Magnetic Resonance Imaging in Differential Diagnosis.

Zedde M, Napoli M, Moratti C, Pavone C, Bonacini L, Cecco G Diagnostics (Basel). 2024; 14(6).

PMID: 38535038 PMC: 10969781. DOI: 10.3390/diagnostics14060618.

Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI.

de Godoy L, Lim K, Rajan A, Verma G, Hanaoka M, ORourke D Cancers (Basel). 2023; 15(18).

PMID: 37760422 PMC: 10526791. DOI: 10.3390/cancers15184453.

Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging.

Liu S, Zhang Y, Kong Z, Jiang C, Wang Y, Zhao D BMC Neurosci. 2022; 23(1):72.

PMID: 36471242 PMC: 9720933. DOI: 10.1186/s12868-022-00750-8.

References

Chawla S, Oleaga L, Wang S, Krejza J, Wolf R, Woo J . Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging. 2008; 20(1):3-8. DOI: 10.1111/j.1552-6569.2008.00307.x. View

van den Bent M . Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol. 2004; 30(6 Suppl 19):39-44. DOI: 10.1053/j.seminoncol.2003.11.024. View

Tate A, Majos C, Moreno A, Howe F, Griffiths J, Arus C . Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med. 2003; 49(1):29-36. DOI: 10.1002/mrm.10315. View

Kapoor G, Gocke T, Chawla S, Whitmore R, Nabavizadeh A, Krejza J . Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol. 2009; 92(3):373-86. DOI: 10.1007/s11060-009-9880-x. View

Henry R, Vigneron D, Fischbein N, Grant P, Day M, Noworolski S . Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol. 2000; 21(2):357-66. PMC: 7975338. View

Palfi S, Swanson K, De Bouard S, Chretien F, Oliveira R, Gherardi R . Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer. 2004; 91(4):745-52. PMC: 2364801. DOI: 10.1038/sj.bjc.6602048. View

Iwamoto F, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M . Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 2008; 88(3):293-8. DOI: 10.1007/s11060-008-9563-z. View

Jenkinson M, Smith T, Joyce K, Fildes D, Du Plessis D, Warnke P . MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology. 2005; 64(12):2085-9. DOI: 10.1212/01.WNL.0000165998.73779.D9. View

Jenkinson M, du Plessis D, Smith T, Joyce K, Warnke P, Walker C . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 2006; 129(Pt 7):1884-91. DOI: 10.1093/brain/awl108. View

10.

Quarles C, Ward B, Schmainda K . Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magn Reson Med. 2005; 53(6):1307-16. DOI: 10.1002/mrm.20497. View

11.

Cairncross J, Macdonald D . Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988; 23(4):360-4. DOI: 10.1002/ana.410230408. View

12.

Hartmann C, von Deimling A . Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res. 2009; 171:25-49. DOI: 10.1007/978-3-540-31206-2_2. View

13.

Engelhard H, Stelea A, Cochran E . Oligodendroglioma: pathology and molecular biology. Surg Neurol. 2002; 58(2):111-7; discussion 117. DOI: 10.1016/s0090-3019(02)00751-6. View

14.

Bromberg J, van den Bent M . Oligodendrogliomas: molecular biology and treatment. Oncologist. 2009; 14(2):155-63. DOI: 10.1634/theoncologist.2008-0248. View

15.

Chawla S, Wang S, Wolf R, Woo J, Wang J, ORourke D . Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol. 2007; 28(9):1683-9. PMC: 8134179. DOI: 10.3174/ajnr.A0673. View

16.

Aldape K, Burger P, Perry A . Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007; 131(2):242-51. DOI: 10.5858/2007-131-242-CAOQLA. View

17.

Lee Y, Van Tassel P . Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol. 1989; 152(2):361-9. DOI: 10.2214/ajr.152.2.361. View

18.

Cairncross J, Ueki K, Zlatescu M, Lisle D, Finkelstein D, Hammond R . Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90(19):1473-9. DOI: 10.1093/jnci/90.19.1473. View

19.

Lev M, Ozsunar Y, Henson J, Rasheed A, Barest G, Harsh 4th G . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004; 25(2):214-21. PMC: 7974605. View

20.

Provencher S . Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001; 14(4):260-4. DOI: 10.1002/nbm.698. View